<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF46D1B5-9EE9-459F-8D6D-68C3987370BD"><gtr:id>EF46D1B5-9EE9-459F-8D6D-68C3987370BD</gtr:id><gtr:name>University Hospitals of Leicester NHS</gtr:name><gtr:address><gtr:line1>Leicester Royal Infirmary</gtr:line1><gtr:line2>Infirmary Square</gtr:line2><gtr:line4>Leicester</gtr:line4><gtr:postCode>LE1 5WW</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1609303A-B817-4C20-9FE6-3BB523B84410"><gtr:id>1609303A-B817-4C20-9FE6-3BB523B84410</gtr:id><gtr:name>Fondazione IRCCS Istituto Nazionale dei Tumori</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FC4AEC24-1D27-41FF-B39A-3E3C5B335512"><gtr:id>FC4AEC24-1D27-41FF-B39A-3E3C5B335512</gtr:id><gtr:name>National Museum of Natural History</gtr:name><gtr:address><gtr:line1>Erbprinzenstrase 13</gtr:line1><gtr:line2>76133</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:department>Genetics</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF46D1B5-9EE9-459F-8D6D-68C3987370BD"><gtr:id>EF46D1B5-9EE9-459F-8D6D-68C3987370BD</gtr:id><gtr:name>University Hospitals of Leicester NHS</gtr:name><gtr:address><gtr:line1>Leicester Royal Infirmary</gtr:line1><gtr:line2>Infirmary Square</gtr:line2><gtr:line4>Leicester</gtr:line4><gtr:postCode>LE1 5WW</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1609303A-B817-4C20-9FE6-3BB523B84410"><gtr:id>1609303A-B817-4C20-9FE6-3BB523B84410</gtr:id><gtr:name>Fondazione IRCCS Istituto Nazionale dei Tumori</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FC4AEC24-1D27-41FF-B39A-3E3C5B335512"><gtr:id>FC4AEC24-1D27-41FF-B39A-3E3C5B335512</gtr:id><gtr:name>National Museum of Natural History</gtr:name><gtr:address><gtr:line1>Erbprinzenstrase 13</gtr:line1><gtr:line2>76133</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/77EEF4BD-474B-43EC-94BE-C3787F15C5BD"><gtr:id>77EEF4BD-474B-43EC-94BE-C3787F15C5BD</gtr:id><gtr:firstName>Nicola</gtr:firstName><gtr:surname>Royle</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0500336"><gtr:id>D0297A03-3EEC-4D41-BF66-D4619031822A</gtr:id><gtr:title>Telomere maintenance pathways and their role in genome stability.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0500336</gtr:grantReference><gtr:abstractText>Most cancer cells have the capacity to replicate indefinitely. This is partly achieved by activation of a telomere maintenance mechanism (TMM) and we are trying to understand the molecular basis of some of these pathways. Telomeres are repetitive DNA sequences that cap chromosomes and so prevent damage to the genome. The majority of tumours activate telomerase or the Alternative Lengthening of Telomeres (ALT) pathway to maintain telomeres but the TMM is unknown in a subset of tumours. In addition the molecular mechanism that underlies ALT is poorly understood. Recently we have shown that activation of the ALT pathway can destabilize other repeated sequences in the genome but the significance of this observation is unclear. Therefore using single telomere and single molecule approaches we plan to investigate telomeric DNA and other sequences in order to elucidate the underlying TMM in tumours. In addition in cell lines we plan to disrupt the expression of genes that are thought to play a role in ALT and study the effect on telomeres and other DNA sequences in the genome. In the long term we hope this will lead to identification of targets for novel anti-cancer therapies.</gtr:abstractText><gtr:technicalSummary>We have shown that human telomere repeat arrays are prone to mutations, with a germline mutation rate of 0.6% per kb. We proposed that the germline mutation process is dominated by intra-allelic events and that inter-allelic recombination is uncommon. Our recent analysis of sequences adjacent to the Xp/Yp telomere, encompassing a hyper variable minisatellite (DXYS14), strongly supports this view. We have also shown the telomere mutation frequency is significantly higher in sporadic colon cancers, increasing to 35% per allele in tumours with defects in mismatch repair (MMR). Again the mutation process appears to be dominated by intra-allelic events. In contrast complex telomere mutations, discovered in cells that use the Alternative Lengthening of Telomeres (ALT) pathway to maintain telomere length, are highly likely to arise by recombination-like processes that underlie ALT. Control of the ALT pathway and genes required for telomere lengthening are poorly understood. Recently we have shown that the MS32 minisatellite, which normally mutates by recombination in the human germline, becomes highly unstable upon activation of the ALT pathway but four other minisatellites remain stable. To investigate the link between the minisatellite and telomere instability in ALT+ cell lines we will measure mutation frequencies at a variety of minisatellites, selected by their location in the genome and the nature of the repeat array (sequence composition, repeat length). To determine whether the destabilization of MS32 is a localized perhaps chromatin mediate effect, we will study other repeated sequences in the vicinity of the MS32 locus and we will examine gene expression in related cell lines with and without ALT activity. We will investigate the frequency of extraordinary MS32 instability in soft tissue and other sarcomas to determine whether it has value as diagnostic marker. We also plan to utilize the MS32 minisatellite as a tool to dissect the ALT pathway. Initially we will disrupt the expression of helicase genes thought to play a role in ALT and study the effect on the mutation rate and profile at the MS32 locus and at single telomeres. We plan to take a similar approach to study the effect of disruption of the MMR pathway on telomere stability and length. Finally we plan to develop PCR based tools for the analysis of a subset of telomeres in the mouse. Such tools will be valuable in the investigation of the ALT pathway and of telomere length dynamics in mutant strains that model some human diseases.</gtr:technicalSummary><gtr:fund><gtr:end>2009-02-12</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-01-13</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>216744</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Leicester Cancer Research UK Centre</gtr:department><gtr:description>Jacqui Shaw</gtr:description><gtr:id>AD5F1710-9778-4483-8C05-85B8DF2C86BA</gtr:id><gtr:impact>doi.org/10.1136/jclinpath-2016-204151</gtr:impact><gtr:outcomeId>58c935b0226500.72933631-1</gtr:outcomeId><gtr:partnerContribution>Shaw contributes expertise in the analysis of circulating cell free tumour DNA and provides access to a GCLP standard laboratory and dedicated equipment for ddPCR. Shaw and team provide training for staff involved in the project.</gtr:partnerContribution><gtr:piContribution>Royle is the academic lead with expertise in telomere biology; makes significant intellectual contribution to the research project involving the molecular characterisation of tumours and other samples that are collected. Royle is also responsible for training clinical and no-clinical staff involved in the project.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Toxicology Unit</gtr:department><gtr:description>Collaboration re TRF2 in ALT+ cells</gtr:description><gtr:id>A87D19A7-9A49-4D73-82B4-E4904E1398E9</gtr:id><gtr:impact>PMID: 18056407</gtr:impact><gtr:outcomeId>68F7469C06F-1</gtr:outcomeId><gtr:partnerContribution>As a result of our collaboration we expanded our expertise, to include the use of shRNA technology.</gtr:partnerContribution><gtr:piContribution>We did the telomere length analysis and cytogenetics to look for chromosome fusions, indicative of uncapped telomeres repaired by non homologous end joining. We contributed to the model that was developed to explain the observations.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fondazione IRCCS Istituto Nazionale dei Tumori</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>ALT in liposarcomas</gtr:description><gtr:id>EA31135F-92AC-4062-9F5B-6D2AD3119087</gtr:id><gtr:impact>PMID: 18311780</gtr:impact><gtr:outcomeId>3D3A4F0A765-1</gtr:outcomeId><gtr:partnerContribution>Our collaborator provided DNA samples and some clinical information from a panel of liposarcomas</gtr:partnerContribution><gtr:piContribution>The work for this project was initiated and conducted in my lab and the results analysed and written by me. Our collaborator kindly provided us with a panel of DNA samples from liposarcomas in which telomere length, telomerase activity and the presence / absence of APBs had been determined.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Museum of Natural History</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Collaboration re CTAGGG repeats</gtr:description><gtr:id>A24A5088-E314-4013-8B09-8EC99DD08D68</gtr:id><gtr:impact>PMID: 19656953 PMID: 19692585</gtr:impact><gtr:outcomeId>96F2038886C-1</gtr:outcomeId><gtr:partnerContribution>Our collaborators conducted some DNA binding and DNA damage assays and showed that the CTAGGG repeats bind efficiently to hPot1 and to other Shelterin components in vitro. in addition they investigated the unusual structure formed by the CTAGGG repeats.</gtr:partnerContribution><gtr:piContribution>My group initiated the invesitgation. We identified the CTAGGG repeats within human telomeres and showed that they cause localized instability in the telomeric DNA in somatic cells and in the germ-line. I proposed the model by which the CTAGGG repeat might cause instability and initiated the collaboration to explore it.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals of Leicester NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UHL Charitable Funds</gtr:department><gtr:description>Robert Ashford</gtr:description><gtr:id>B90315B1-592E-46E0-95BA-03D718A2BE42</gtr:id><gtr:impact>Ethically approved research project: Genetic profile and telomere characteristics and of high-grade soft tissue sarcomas
REC reference:14/NE/1192; IRAS ID: 141820.

doi:10.1136/jclinpath-2016-204151</gtr:impact><gtr:outcomeId>58c927aae339f4.01088895-1</gtr:outcomeId><gtr:partnerContribution>Mr Ashford (Consultant Orthopaedic and Musculoskeletal Tumour Surgeon in UHL Trust) is the lead applicant on an ethically approved research project: Genetic profile and telomere characteristics and of high-grade soft tissue sarcomas (IRAS 141820). He is responsible for all the clinical aspects of the project. He facilitates the recruitment of patients to the study and is responsible for compliance with the ethical considerations surrounding informed consent; for training and supervision of staff involved in sample collection.</gtr:partnerContribution><gtr:piContribution>Royle is a co-applicant an ethically approved study with Ashford (Genetic profile and telomere characteristics and of high-grade soft tissue sarcomas; IRAS 141820). Royle is the academic lead on the laboratory research project involving the molecular characterisation of tumours and other samples that are collected. Royle makes significant intellectual contribution to the research project and is responsible for training clinical and no-clinical staff involved in the project.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Short talk at Genetics 50th Celebrations: Open Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>DC9F7742-5DCE-4038-81D9-48A5B539770F</gtr:id><gtr:impact>Talk stimulated interest, evidenced by comments received following the event

Not measured</gtr:impact><gtr:outcomeId>54621738f09792.31184673</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Flagship lecture 1st year undergraduates</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6CF50A1E-C430-442D-A7AB-278AA4A87219</gtr:id><gtr:impact>Approximately 280 first year undergraduates in Biological Sciences attended a flagship lecture entitled: Genetics, Ageing &amp;amp; Telomeres: the ends insight</gtr:impact><gtr:outcomeId>56ddd93329d970.55618734</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Barwell- Developing a shared vision for Genomic Medicine</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CF23D711-2A57-4A14-BAF6-D346B129222D</gtr:id><gtr:impact>Approximately 80 people attend this meeting with the aim of identifying how genomic medicine could be take forward and be integrated in to the NHS now and in the future. Several ideas emerged including working closely with a neighbouring country to form an international Genomic Medicine Centre that could us mutually beneficial in understanding how best to store and used genomic data now (arising from the 100,000 genome project) and in the future. In addition ideas about provision of short modular training courses for NHS staff were proposed.</gtr:impact><gtr:outcomeId>58c96631196584.91087473</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Outreach to primary school in Leicester</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>9B907FC5-A7C6-419C-820C-D0E1691ADFFC</gtr:id><gtr:impact>I organized a half day visit to the Department of Genetics for 60 children (year 6) and teachers. This was done in conjunction with a CETL 'Genie' at University of Leicester.

Feed back was very positive. Hope this event served to enthuse young pupils about science and about studying at University.</gtr:impact><gtr:outcomeId>4388BA8DA77</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Hope - outreach event</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>7FD76CA5-BA51-4935-AB5C-28091A4B115E</gtr:id><gtr:impact>Estimated 70 adults attend this event and they were able to engage various genetics outreach events and view posters that explain various projects funded by the charity including our work of soft tissue sarcomas.</gtr:impact><gtr:outcomeId>58c95530ac2c37.41767131</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Outreach to secondary school in Leicester</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C6351046-6E8D-4BB6-AC8B-B63CD7229A31</gtr:id><gtr:impact>I organised and conducted a practical class in a science club at a local secondary school (duration 2hrs; 35 students + teachers).

Feed back was very positive. Hope this event served to enthuse pupils about science and about studying at University.</gtr:impact><gtr:outcomeId>F96C6A99101</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CRUK- fundraising events</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>FA0EB9F7-07EA-4DDE-AA3A-9578CFF719E3</gtr:id><gtr:impact>Informed members of public about role of telomeres in maintenance of genome stability an role in cancer formation / progression.

Helped to raise the profile of cancer research conducted at the University of Leicester</gtr:impact><gtr:outcomeId>9C0B421B93E</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>421204</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0901657</gtr:fundingRef><gtr:id>439F10A2-B3A9-4573-9FF4-CBF9DC1967A4</gtr:id><gtr:outcomeId>DB252LWRm1N0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>6000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UHL Charitable Funds</gtr:department><gtr:description>UHL Charitable Funds - Foxtrot</gtr:description><gtr:end>2017-01-02</gtr:end><gtr:fundingOrg>University Hospitals of Leicester NHS Trust</gtr:fundingOrg><gtr:id>FA272018-4618-44BB-AC03-C57F3A5ADB53</gtr:id><gtr:outcomeId>5460dc7b2e8258.74950848</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Hope Against Cancer, Leicestershire and Rutland</gtr:description><gtr:end>2018-05-02</gtr:end><gtr:fundingOrg>Hope Against Cancer (Rutland and Leicestershire)</gtr:fundingOrg><gtr:id>B7462E24-2742-496D-945E-FBF3A35CF9E9</gtr:id><gtr:outcomeId>58c94b8fa01a99.18901998</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UHL Charitable Funds</gtr:department><gtr:description>UHL Charitable Funds - Foxtrot</gtr:description><gtr:end>2018-04-02</gtr:end><gtr:fundingOrg>University Hospitals of Leicester NHS Trust</gtr:fundingOrg><gtr:id>BAB477FD-C31E-450D-918C-622950DD44E3</gtr:id><gtr:outcomeId>56dec0d144f307.83484389</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>140000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Eastley-MRC Clinical training fellowship</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/N02107X/1</gtr:fundingRef><gtr:id>7D0AB223-62A1-44E4-8D38-6AFEC3586C00</gtr:id><gtr:outcomeId>58c98387d2b203.88409924</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>9000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Leicester Centre Development Fund</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>E3FF280A-E7B7-4F21-B9FE-CB6C24B9CF6C</gtr:id><gtr:outcomeId>5460db6b254971.50156815</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>180000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Project Grant</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C17992/A8641</gtr:fundingRef><gtr:id>EC08E8A5-BEBE-48F0-9119-0DB6F34B4FA9</gtr:id><gtr:outcomeId>572AFB53A680</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>The method combines single molecule telomere amplification (smSTELA) with characterisaton of sequence-variant telomere repeats (TVR-PCR). This facilitates detailed telomere mutation analysis on DNA samples from human tissues samples.</gtr:description><gtr:id>3A99E739-5E6B-405B-9F79-3E49DADCEE53</gtr:id><gtr:impact>Using this approach we have been able to make a significant contribution to understanding the turnover of human telomeric DNA in normal human tissues and in tumours.</gtr:impact><gtr:outcomeId>D1148938F37</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>single molecule telomere analysis</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>362F5CA4-8CE5-4D03-97E7-C868A5F0E30D</gtr:id><gtr:title>Deficiency in DNA mismatch repair increases the rate of telomere shortening in normal human cells.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4867b5a524a4d4b64c24ebc9fb1c48d"><gtr:id>c4867b5a524a4d4b64c24ebc9fb1c48d</gtr:id><gtr:otherNames>Mendez-Bermudez A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>PNFioHGi9eK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A48B45D-B824-4670-B8DE-21DD9FE8425F</gtr:id><gtr:title>Lack of TRF2 in ALT cells causes PML-dependent p53 activation and loss of telomeric DNA.</gtr:title><gtr:parentPublicationTitle>The Journal of cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a10d825a81423a13571a4af0f359eeb"><gtr:id>4a10d825a81423a13571a4af0f359eeb</gtr:id><gtr:otherNames>Stagno D'Alcontres M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9525</gtr:issn><gtr:outcomeId>90B3DE8119E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89D3FE1B-D039-4AE0-854A-BF7713A92E80</gtr:id><gtr:title>Evidence for alternative lengthening of telomeres in liposarcomas in the absence of ALT-associated PML bodies.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/028fd847b82ed844018ff4568a3ecf41"><gtr:id>028fd847b82ed844018ff4568a3ecf41</gtr:id><gtr:otherNames>Jeyapalan JN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>1AF6DF8B8DD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E2F44DF-D012-4EF4-9D6F-6D6EC019DE62</gtr:id><gtr:title>The roles of WRN and BLM RecQ helicases in the Alternative Lengthening of Telomeres.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4867b5a524a4d4b64c24ebc9fb1c48d"><gtr:id>c4867b5a524a4d4b64c24ebc9fb1c48d</gtr:id><gtr:otherNames>Mendez-Bermudez A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>pm_14448_28_22989712</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A545A994-663B-4221-932C-9FED39CFADA6</gtr:id><gtr:title>Mutation mechanisms that underlie turnover of a human telomere-adjacent segmental duplication containing an unstable minisatellite.</gtr:title><gtr:parentPublicationTitle>Genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7012f4ebcae59567f18b99e6cb63d821"><gtr:id>7012f4ebcae59567f18b99e6cb63d821</gtr:id><gtr:otherNames>Hills M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0888-7543</gtr:issn><gtr:outcomeId>3363760BF45</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94DCDC96-F31C-4AA2-92E1-47361F0629E6</gtr:id><gtr:title>Human telomeres that contain (CTAGGG)n repeats show replication dependent instability in somatic cells and the male germline.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4867b5a524a4d4b64c24ebc9fb1c48d"><gtr:id>c4867b5a524a4d4b64c24ebc9fb1c48d</gtr:id><gtr:otherNames>Mendez-Bermudez A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>E352E278663</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>634F91C3-E549-4FFA-ACC7-84AF848F41F2</gtr:id><gtr:title>Telomere maintenance in soft tissue sarcomas.</gtr:title><gtr:parentPublicationTitle>Journal of clinical pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98012d89a9623e1269fde2aa77fb2312"><gtr:id>98012d89a9623e1269fde2aa77fb2312</gtr:id><gtr:otherNames>Eastley N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0021-9746</gtr:issn><gtr:outcomeId>58c82d34bf3670.28105080</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F74BB4C-94EF-4CD2-A756-C2316AF8CB7F</gtr:id><gtr:title>Sequence variant (CTAGGG)n in the human telomere favors a G-quadruplex structure containing a G.C.G.C tetrad.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1c1f97cde834cb8fdb7bd4dce8cbcc9"><gtr:id>e1c1f97cde834cb8fdb7bd4dce8cbcc9</gtr:id><gtr:otherNames>Lim KW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>C1B21E7EB31</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500336</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>